Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in Stem Cell dealmaking



2.1. Introduction

2.2. Stem Cell partnering over the years

2.3. Most active Stem Cell dealmakers

2.4. Stem Cell partnering by deal type

2.5. Stem Cell partnering by therapy area

2.6. Deal terms for Stem Cell partnering

2.6.1 Stem Cell partnering headline values

2.6.2 Stem Cell deal upfront payments7

2.6.3 Stem Cell deal milestone payments

2.6.4 Stem Cell royalty rates



Chapter 3 – Leading Stem Cell deals



3.1. Introduction

3.2. Top Stem Cell deals by value



Chapter 4 – Most active Stem Cell dealmakers



4.1. Introduction

4.2. Most active Stem Cell dealmakers

4.3. Most active Stem Cell partnering company profiles



Chapter 5 – Stem Cell contracts dealmaking directory



5.1. Introduction

5.2. Stem Cell contracts dealmaking directory



Chapter 6 – Stem Cell dealmaking by technology type



Chapter 7 – Partnering resource center



7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking



Appendices



Appendix 1 – Stem Cell deals by company A-Z



Appendix 2 – Stem Cell deals by stage of development



Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation



Appendix 3 – Stem Cell deals by deal type



Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty



Appendix 4 – Stem Cell deals by therapy area



Appendix 5 –Deal type definitions



About Wildwood Ventures



Current Partnering

Current Agreements

Recent report titles from Current Partnering



Table of figures



Figure 1: Stem Cell partnering since 2014

Figure 2: Active Stem Cell dealmaking activity since 2014

Figure 3: Stem Cell partnering by deal type since 2014

Figure 4: Stem Cell partnering by disease type since 2014

Figure 5: Stem Cell deals with a headline value

Figure 6: Stem Cell deals with an upfront value

Figure 7: Stem Cell deals with a milestone value

Figure 8: Stem Cell deals with a royalty rate value

Figure 9: Top Stem Cell deals by value since 2014

Figure 10: Most active Stem Cell dealmakers since 2014

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events